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Abstract
Point-of-care testing (POCT) remains under scrutiny
by healthcare professionals because of its ill-tried,
young history. POCT methods are being developed by
a few major equipment companies based on rapid
progress in informatics and nanotechnology. Issues
as POCT quality control, comparability with standard
laboratory procedures, standardisation, traceability
and round robin testing are being left to hospitals. As
a result, the clinical and operational benefits of POCT
were first evident for patients on the operating table.
For the management of cardiovascular surgery
patients, POCT technology is an indispensable aid.
Improvement of the technology has meant that clini-
cal laboratory pathologists now recognise the need
for POCT beyond their high-throughput areas.
Clin Chem Lab Med 2006;44:1060–5.
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Introduction
A current trend in laboratory medicine is to perform
patient tests near to the point at which care is ren-
dered, commonly referred to as point-of-care testing
(POCT). POCT procedures can take place in various
locations, such as in the patient’s home, pharmacies,
the physician’s office, and satellite laboratories
(kiosks) in the emergency department of hospitals (1,
2) as well as in operating theatres of various surgical
specialties. In mainland China, POCT has become
popular (3). The healthcare industry is currently focus-
ing on analytical equipment in the POCT setting, with
the development of clinical laboratory instrumenta-
tion and reagents for performing clinical chemistry
tests (www.researchandmarkets.com, www.made-in-
china.com).
The present summary is an analysis of the profi-
ciency of POCT during heart surgery. Mobile labora-
tory analysers in the operating room have become an
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integral part of the equipment needed for state-of-the-
art perioperative management of heart surgery
patients, especially those on extracorporeal blood cir-
culation (ECC). Using POCT, the pre-analytical step for
optimised storage of blood samples has become irrel-
evant because of the advantage of immediate testing.
However, determining the best drawing site, i.e., from
catheters or from extracorporeal circuitry tubing or its
built-in stopcocks, remains a relevant consideration
(4, 5). POCT of blood cells might feature ECC system-
specific red blood cell (RBC) and/or platelet alterations
(6). Guidelines and suggestions for specimen collec-
tion from indwelling catheters or cannulae have been
put forward by the International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC). In Europe,
the register for specialties in clinical chemistry and
laboratory medicine EC4 now comprises approxi-
mately 1500 specialists in this field, with increasing
concern being expressed regarding POCT quality (7).
POC diagnosis (POCD), complemented by POC mon-
itoring (POCM), has been suggested as a means of
improving the capacity of anaesthetists and cardio-
technicians to react appropriately in the case of
abnormal laboratory values. The need for establishing
evidence-based POCT practice is now covered by the
National Academy of Clinical Chemistry (NACB)
guidelines (www.nacb.org/lmpg/poct_LMPG_draft_
word.stm). Although it is becoming more widely
accepted, POCT is still often under the scrutiny of reg-
ular clinical pathology laboratory staff (8). Inadequate
monitoring of quality controls, as well as economic
aspects, have been put forward as arguments for
avoiding POCT. On the contrary, those in favour of
POCT focus on the increased efficiency and availa-
bility of test results, which allow therapeutic decisions
without delay, an aspect that is most crucial for the
care of cardiovascular surgery patients.
Coagulation
POCT-supported procedures, such as preparation of
autologous fibrinogen and platelets, depend on coag-
ulation tests (Table 1). There are two methods cur-
rently in use: activated clotting time and in special
cases thrombelastography (TEG).
Activated clotting time (ACT)
During the use of oxygenator and filters and their
associated surfaces for ECC, high levels of heparin are
required to maintain blood in a fluid state (typically
2.0–4.0 U/mL). In the early days of cardiac surgery,
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Table 1 Random choice of instruments and assays for monitoring anticoagulants in cardiopulmonary bypass in a POCT
setting.
Instrument Assay Bias
Hemochron Response Prothrombin time (PT) and activated During bypass acceptable, after bypass
partial thromboplastin time (APTT) questionable (9)
HemoTeca Activated clotting time Heparin
ACT Plus automated coagulation
timer system
TAS analyser (10) Heparin management test Heparin
TAS analyser Ecarin clotting time Thrombin inhibitors
Platelet function analyser Platelet function Aspirin, gpIIb/IIIa inhibitors
Thrombelastograph Clot signature and platelet function Aspirin, gpIIb/IIIa inhibitors, aprotinin
Hepcon Protamine neutralisation Protamine
a Two instruments for which the producer proposes measurement of the same parameters cannot necessarily be used inter-
changeably (11).
the dose of heparin required and its reversal with pro-
tamine were calculated using a formula. The problem
with such a mathematical rule was that the doses cal-
culated could not predict the individual patient’s reac-
tion to heparin, which can vary by as much as
20–35%. Therefore, as early as 1966, the activated
clotting time was developed by Hattersley (12) and a
dosing scheme based on the 480-s target time was
established. The test is performed in a hand-held
glass tube, which is periodically inverted. The start
and end of heparinisation, which is reversed by pro-
tamine, are timed between cannulation of the aorta
and the right atrium using an average dosage of
400 U heparin/kg body weight. The side effects of
ECC, as a result of the limited biocompatibility of the
circuitry’s artificial surfaces (13), include activation of
the complement and fibrinolytic systems.
In 1988, Hemochron released the first automated
ACT device. Pre-operative testing with an ACT device
effectively identifies the patient’s reaction to heparin
so that overdosing and/or underdosing during sur-
gery can be avoided. Accurate ACT POCT reduces
postoperative blood loss and the requirement for
transfusion of RBCs, platelet concentrate and fresh
frozen plasma (14). Therefore, protamine use and re-
exploration for non-specific surgical bleeding can be
reduced to a minimum.
Because ACT has become the gold standard for
monitoring heparin during ECC, its success has led to
the development of a series of alternative assays
based on the same concept. Usually these assays are
performed with different instrumentation and with
celite or kaolin as the coagulation activator. Each
commercial activator initiates factor XII activation in
a different manner, so the various ACTs may have
different sensitivities and specificities.
Factors that are directly related to heart surgery can
influence ACT (15). In fact, the widespread use of fibri-
nolysis inhibitors such as aprotinin and ´-amino-
caproic acid (16) has made it necessary to keep track
of their activity using POCT. Linear regression and
error analysis were used to compare POCT devices
with standard laboratory methods (9) and the com-
parison showed favourable results for POCT. Further-
more, patients with infectious endocarditis, surgery
on the thoracic aorta using hypothermia (17) and
selective circulation arrest, or patients with prior
heparinisation need to be continuously monitored
using ACT.
POCT instruments that monitor patients treated
with vitamin K antagonists are not useful in the oper-
ating theatre; the accuracy of these instruments has
recently been reviewed elsewhere (18, 19). For POCT
in the operating theatre or the paediatric cardiac
intensive care unit, a number of instruments from dif-
ferent producers are on the market (20–22).
Thrombelastography (TEG)
Modern TEG machines electronically identify the pro-
cess of clot formation from the initial point of fibrin
formation and platelet aggregation until the clot is
lysed (23).
TEG may be useful during aortic surgery or when a
balloon is inserted into the aorta to complement
insufficient cardiac output or to initiate the function of
an artificial heart. In addition, the side effects of ECC
components caused by roller pumps, centrifugal
pumps, axial pumps and other devices can be moni-
tored by POCT, including TEG, and can be immedi-
ately corrected if necessary.
In our clinic we use the Roteg analyser (Axon Lab
AG, Zurich, Switzerland). In contrast to conventional
TEG, the Roteg system works based on the addition
of activators and inhibitors of coagulation, and thus
allows for differential measurement of platelet func-
tion. Impedance-based measurements of platelet
aggregation might extend the diagnostic spectrum to
exploration of specific platelet functions. Cardiac sur-
gery patients often undergo substantial haemodilu-
tion, resulting in intraoperative haematocrit values
between 0.15 and 0.20. We have recently found when
using RoTEM (Pentapharm, Munich, Germany) that
hydroxyethlystarch (HES, Voluven; Fresenius Kabi,
Stans, Switzerland) impairs the coagulation system
more than saline or Ringer-lactate solution does when
used for volume replacement (24). Surgical interven-
tions that require hypothermia, with body tempera-
tures between 188C and 228C, need POCT TEG
monitoring of platelet function. Recently, TEG has
been used for the reversal of heparin effects based on
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the addition of heparinase to the reagent cup, where-
by the contribution of hyperfibrinolysis to clot decom-
position becomes readily apparent. In these cases, the
diagnostic value of TEG depends on the contact acti-
vator used: differential usage of ellagic acid tissue fac-
tor in drawing diagnostic conclusions becomes
possible (25), thereby reducing transfusion require-
ments (26, 27). POCT TEG results can be used to
determine the prescription of costly recombinant fac-
tor VIIa (rFVIIA) to counterbalance HES-induced dilu-
tional coagulopathy.
Electrolytes and blood gases
The patient’s ventilation status is monitored by elec-
trolyte, blood gas analysis (BGA) and pH measure-
ments and is evaluated during and immediately after
heart surgery. Such equipment is also found as POCT
devices in respiratory laboratories. In cardiac surgery,
electrolytes are predominantly measured to control
the performance of artificial lung oxygenators. With
the development of more complex surgical interven-
tions, such as those in which the complete thoracic-
abdominal aorta down to the aorto-iliacal bifurcation
is replaced, control of visceral and peripheral perfu-
sion is mandatory. Similarly, the influence of vaso-
active drugs and other anaesthetic interventions can
be continuously controlled using POCT BGAmeasure-
ments.
Electrolytes
In operations on a resting heart, a potassium-enriched
blood-cardioplegic solution is infused every 20 min
into the coronary arterial circuitry; such myocardial
protection prevents the occurrence of uncontrolled
ischaemia during cardiac arrest. The infusion of this
solution may lead to myocardial, and sometimes even
systemic hyperkalaemia, which may result in arryth-
mias that are difficult to control. Measurement of
serum potassium concentrations immediately after
infusion of the potassium-enriched solution is there-
fore important for the immediate correction of kalae-
mia. Avalanche and drowning victims usually present
with hyperkalaemia, with prognosis based on the
degree and speed of correction of such hyperkalae-
mia. For avalanche victims, POCT BGA (see below) is
performed to distinguish wet snow from powder
snow. The former implies poorer prognosis, since the
asphyxia resembles drowning, with decreased pO2
and increased pCO2 followed by cardiac arrest,
whereas victims of powder snow are subject to hiber-
nation, which is likely to be treatable once the victim
is re-warmed using ECC, much as for cardiac surgery
(28). In newborns undergoing heart surgery, serum
potassium is important and hyperkalaemia is usually
caused by transfusing RBCs stored for more than
10 days after donation. In these cases, serum potas-
sium levels need to be monitored at the operating
table and corrected, if necessary, by insertion of a
haemodialysis filter into the ECC. Other interventions
that require tight potassium control are regional per-
fusion treatments in the case of acute obstruction of
a lower limb or in severe acidosis (Leriche syndrome).
Lung arterial thrombendectomies or operations per-
formed in deep hypothermic cardiac arrest, such as
for replacement of the aorta ascendens, aortic arch
and aorta abdominalis, depend on POCT. Cardiople-
gia performed with autologous blood is carried out
with hyperkalaemic sodium chloride mixed with
blood 1:4, whereas the pure hyperkalaemic solution
does not contain blood. Upon passage through the
coronaries, these solutions reach the right atrium and
become mixed with the patient’s whole blood vol-
ume. With crystalloid cardioplegia, a large infusion
volume of 2000 to 3000 mL is infused which leads to
severe hyponatraemia (-120 mmol/L).
Correction of hyponatraemia, especially in trans-
plant recipients, is slow and constantly monitored
using POCT, as sodium levels need to be closely con-
trolled. In fact, we control sodium levels until the end
of ECC and then return them to preoperative values.
Using such a strategy, postoperative patient con-
sciousness can also improve (avoidance of postper-
fusion syndrome).
Determining the sodium concentration remains an
important diagnostic tool for monitoring possible
anaphylactic side effects. Differential diagnosis
between idiopathic vasoplegia, anaphylactic reaction
towards plasma expanders, and transfusion-related
acute lung injury (TRALI) by administration of fresh
frozen plasma (29) and/or drugs (aprotinin), under
ECC conditions is difficult. Preoperative sodiummeas-
urements are important in the case of intercurrent
haematocrit increase (extravasal volume shift), which
may truly reflect anaphylactic reaction and needs to
be treated with large volume substitution, noradren-
alin and corticosteroids. Calcium and magnesium ion
concentrations should be maintained at preoperative
levels throughout the intervention and therefore need
to be continuously measured by POCT with the aim
of maintaining optimal conditions for normal myo-
cardial contractility and regular rhythm postopera-
tively.
Blood gas analysis
The most vital laboratory parameters during open
heart surgery are routine BGAs, which include repeat-
ed measurements of pO2, pCO2, HCO3–, pH and base
excess. In leading clinics, blood gases are continu-
ously monitored, allowing response to diagnostic,
therapeutic and prognostic criteria. In addition to elec-
trolytes, BGA allows estimation of the patient’s con-
dition and the efficacy of ECC (2, 30) by the
measurement of central mixed venous pO2 saturation.
Since as a rule all heart surgery procedures are per-
formed under either moderate (328C) or, in special
cases, deep (208C) hypothermia, BGA is of special
interest. Upon installation of hypothermia two strat-
egies are pursued:
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1. The alphastat value, based on maintaining non-
corrected pH 7.40 and pCO2 of 40 mm Hg meas-
ured at 378C. Such a strategy ensures constant
relative respiratory alkalosis by maintaining CO2
content and a constant Hq/OH– ratio in the blood,
which simulates poikilothermia. The degree to
which key plasma proteins such as highly active
enzymes are ionised is important for their func-
tional performance. The true pH value of arterial
blood decreases by 0.0147 pH units for each 18C
increase in body temperature. Thus, a reduction
in body temperature by 108C will lead to a rele-
vant increase in pH of 0.15. In contrast, O2 and
CO2 decrease. To reach alphastat during hypo-
thermic ECC, relative hyperventilation must be
maintained (30).
2. The pH-stat value, based on maintaining pH 7.40
and pCO2 of 40 mm Hg at true rectal temperature
corrected to 378C. Such a strategy maintains that
normal pH values of 7.40 and pCO2 of 40 mm Hg
at 378C are also measured during hypothermia.
Relative respiratory acidosis then occurs, where-
by the acid-base equilibrium simulates hiberna-
tion. To reach pH-stat during ECC, relative
hypoventilation and the addition of CO2 to the
gas mixture for the artificial lung are necessary.
New developments are focusing on displacement
of air from the heart chambers by controlling the
inflow of the denser CO2. Such a deaeration pro-
cedure affects the blood gas profile, and thus
immediately controlled POCT BGA is indispens-
able for patient monitoring.
Haematocrit
Besides BGA, haematocrit is controlled regularly eve-
ry 20 min; appropriate O2 supply is linked to blood
gas physiology, as well as to O2 transport capacity.
The O2-dissociation curve must be maintained within
physiological limits as best as possible under ECC
conditions using an artificial lung. Should the O2 sup-
ply fail, lack of O2 in the terminal tissue could lead to
cerebral ischaemia and, in some cases, cerebral
hypoxia, which could result in oedema and/or the
development of microemboli.
In addition to controlling hypothermia, the haema-
tocrit and BGA also serve as a general surveillance of
the patient and of the function of the ECC machine.
Thus, failure of an artificial lung or various low-per-
fusion situations, e.g., cannulation of the wrong
lumen on aortic dissection, can be recognised and
immediately corrected. If the intraoperative haema-
tocrit value falls too low, blood transfusion, most like-
ly with RBC concentrates, becomes necessary, which
is referred to as a transfusion trigger (31).
Expert opinion
We conclude that without POCT, state-of-the-art heart
surgery is not possible. Just as critically ill patients in
the ICU require laboratory results in real time, those
on the operating table of a cardiac surgeon depend
on immediate results of laboratory tests. There are
three main sources of errors: operator incompetence,
use of uncontrolled reagents and non-adherence to
test procedures. The likelihood that such errors affect
outcomes can be amplified by rapid POCT results fol-
lowed by immediate, imprudently prescribed therapy
(32, 33). As yet, POCT is not perfect. Additional POCT
improvements in the operating theatre will require
versatile instruments that have the same accuracy as
the instrumentation used in clinical pathology labo-
ratories. Quality maintenance involving regular test-
ing of blinded controls and documented results is
necessary to meet quality control requirements. POCT
must be subject to local, national and international
ISO-certified round robin testing (34). Communication
between technicians in the operating theatre and cen-
tral laboratory pathologists is required (35). The safe-
ty of POCT is also dependent on the training of the
healthcare professionals who perform the tests. In
certain countries, task forces are at work that are con-
trolled by Committees for Standards. A recent ques-
tionnaire issued to several hundred participants
targeted such professionals as nurses, laboratory sci-
entists, pharmacists and general practitioners (36). In
addition to internal quality control, we advocate sim-
ilar control mechanisms to be issued for anaesthetists
and cardiotechnicians who care for heart surgery
patients (37). The cardiotechnician’s job description
should include monitoring of vital parameters with
analysis of basic haematology and clinical chemistry.
The University of Texas now tests their employees for
proficiency using an intranet-type questionnaire
(http://www.utmb.edu/poc/online.htm).
The values obtained by POCT need to be docu-
mented in the patient’s history, i.e., on an electronic
health record (EHR) spreadsheet with traceability, so
that they can be referred to during the patient’s peri-
operative care. At our hospital, laboratory rules, in
effect, focus on quality control, with constant and
reproducible criteria for the equipment of the per-
manent clinical pathology laboratory as well as the
POCT service. These rules also relate to the overall
strategy of the hospital, as well as health insurance
and care standards. A permanent expert group is
responsible for assuring quality control.
Outlook
The direction of POCT in the operating theatre should
evolve on four tracks. (i) Industry should design inte-
grated POCT diagnostic equipment suited to the
needs of the operating theatre for the most important
surgical disciplines, such as cardiothoracic, orthopae-
dic, neurological and visceral surgery. (ii) Cost-effect-
iveness, ease of use, user accuracy and precision
criteria for test results should be further developed.
Users, if not primarily trained as laboratory techni-
cians, should have to pass licensing tests. (iii) POCT-
specific regulations and guidelines for quality control
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procedures should be recommended and implement-
ed on an international level. (iv) Local partnerships
between laboratory professionals, surgeons, anaes-
thetists and cardiotechnicians should be developed.
Highlights
POCT is essential in following up cardiovascular sur-
gery patients in the operating theatre. POCT needs to
be fully approved by clinical laboratory specialists not
present during the operation. Instead of competing
with non-licensed personnel, trained laboratory per-
sonnel need to instruct and organise teaching events
for anaesthetists and cardiotechnicians. Round robin
testing must bring POCT results to the level of inter-
national comparable laboratory results generated in
the operation theatre. Standard preparations sent
around the globe should be measured with POCT
equipment and made available for EHR tracing.
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